FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2581341171> ?p ?o ?g. }

• W2581341171 abstract "Abstract Abstract 2651 Background and objectives [18F]fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) is confirmed as a useful functional imaging tool for staging and response assessment in Hodgkin lymphoma and Diffuse Large B-Cell Lymphoma. Despite FL is accounted among FDG-avid lymphomas few studies have been performed to investigate how FDG-PET can be used in initial staging of FL patients. We conducted a retrospective analysis to investigate the role of FDG-PET in the initial staging of FL. Patients and methods The study was designed as a retrospective unplanned analysis of patients with newly diagnosed FL enrolled in the FOLL05 phase III trial (NCT00774826) and randomized to one of the three study arms (R-CVP. R-CHOP, R-FM). To be included in the study patients should have confirmed eligibility for the FOLL05 trial, have available data on clinical presentation, treatment details and results, and on follow-up. Baseline staging had to be performed with contrast-enhanced Computed Tomography (CT), with CT-PET, and with Bone Marrow (BM) biopsy. For study purposes disease extension at baseline was defined independently for both CT and PET using on local report and interpretation; only for difficult cases images were centralized and reviewed. For each exam nodal sites (NS) were counted according to the FLIPI schema. NS were considered as positive if greater than 1.5 cm in their maximum transverse diameter at CT or, using PET, if FDG avid or if they had disappeared at the end of treatment. Extranodal sites (ENS) were counted on an organ basis and were considered positive at CT in case of nodular involvement or in case of organ enlargement not otherwise justified. Extranodal involvement at PET was considered for sites showing avidity for FDG not justified by conditions other than FL. Conventional Ann Arbor (AA) staging was based on CT scan assessment only. PET and CT scan results were compared using the kappa-statistic measure of interrater agreement (IR), and the level of agreement was defined by the Koch Landis scale. Results Among 534 patients enrolled in the FOLL05 trial, 122 cases fulfilled eligibility criteria for this study. All but 2 cases were confirmed as FDG avid at PET scan; these two cases were not used for staging comparison. Median age of patients was 57 years (range 33–74), 33% were older than 60 years, 48% were males. Bone marrow biopsy was positive in 52%. Using CT, AA stage was III-IV in 77% of cases. Fifty-two percent, 36%, and 12% of cases had less 0–4, 5–8, and >8 NS, at CT, respectively. Overall CT scan allowed the identification of 48 ENS in 36 patients (30%); 2 or more ENS were described in 8 patients (6%); most frequent ENS were spleen (52%), liver (10%), skin/soft tissue (8%) and GI tract (6%). Using PET 38%, 37%, and 25% of cases had 0–4, 5–8, >8 NS, respectively. PET allowed the identification of 88 ENS in 55 patients (46%) and 2 or more ENS were found in 17 patients (14%). Most frequent ENS at PET were bone (35%), spleen (30%), GI tract (10%), and skin/soft tissue (7%). Classifying patients according to the number of NS (0–4, 5–8, >8) agreement between CT and PET was fair (IR= 61%, Kappa=0.39). Agreement between CT and PET for ENS (grouped as 0, 1, and >1) was also fair (IR= 63%, Kappa=0.31) and improved to moderate when also details on BM histology were considered (IR 82% K=0.4). When PET was used independently of CT to define AA stage a moderate agreement was achieved with CT (IR=76%, kappa= 0.58): in particular 22 cases (18%) were upstaged with PET while only 6 (5%) were downstaged; seventeen out of 25 (68%) patients were reclassified by PET as stage III-IV from a previous localized stage. Looking at FLIPI, 22%, 41%, and 37% were classified by CT as having score of 0–1, 2, and 3–5, respectively. The use of PET modified CT based FLIPI index in 26% of cases, with a substantial agreement between PET and CT (IR=74%, kappa=0.61). FLIPI2 index is not affected by the use of PET. Conclusions The results of this study confirm FL as a FDG-avid disease. The use of PET for the initial staging of patients with FL seems to provide a more accurate definition of disease extent compared with CT. The clinical usefulness of adding PET to the initial staging of FL needs to be further investigated. Disclosures: Di Raimondo: Celgene: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau." @default.
• W2581341171 created "2017-02-03" @default.
• W2581341171 creator A5005592897 @default.
• W2581341171 creator A5015840872 @default.
• W2581341171 creator A5016751546 @default.
• W2581341171 creator A5016794322 @default.
• W2581341171 creator A5016803459 @default.
• W2581341171 creator A5019034145 @default.
• W2581341171 creator A5022153283 @default.
• W2581341171 creator A5022446655 @default.
• W2581341171 creator A5027811958 @default.
• W2581341171 creator A5029722841 @default.
• W2581341171 creator A5031524718 @default.
• W2581341171 creator A5031900268 @default.
• W2581341171 creator A5034393745 @default.
• W2581341171 creator A5034680061 @default.
• W2581341171 creator A5035398527 @default.
• W2581341171 creator A5036985315 @default.
• W2581341171 creator A5041745367 @default.
• W2581341171 creator A5044869604 @default.
• W2581341171 creator A5045518627 @default.
• W2581341171 creator A5045569134 @default.
• W2581341171 creator A5049017377 @default.
• W2581341171 creator A5056272944 @default.
• W2581341171 creator A5065993610 @default.
• W2581341171 creator A5070003191 @default.
• W2581341171 creator A5081879832 @default.
• W2581341171 creator A5082045927 @default.
• W2581341171 creator A5084298817 @default.
• W2581341171 creator A5089614080 @default.
• W2581341171 creator A5091882595 @default.
• W2581341171 date "2011-11-18" @default.
• W2581341171 modified "2023-10-01" @default.
• W2581341171 title "The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi" @default.
• W2581341171 doi "https://doi.org/10.1182/blood.v118.21.2651.2651" @default.
• W2581341171 hasPublicationYear "2011" @default.
• W2581341171 type Work @default.
• W2581341171 sameAs 2581341171 @default.
• W2581341171 citedByCount "0" @default.
• W2581341171 crossrefType "journal-article" @default.
• W2581341171 hasAuthorship W2581341171A5005592897 @default.
• W2581341171 hasAuthorship W2581341171A5015840872 @default.
• W2581341171 hasAuthorship W2581341171A5016751546 @default.
• W2581341171 hasAuthorship W2581341171A5016794322 @default.
• W2581341171 hasAuthorship W2581341171A5016803459 @default.
• W2581341171 hasAuthorship W2581341171A5019034145 @default.
• W2581341171 hasAuthorship W2581341171A5022153283 @default.
• W2581341171 hasAuthorship W2581341171A5022446655 @default.
• W2581341171 hasAuthorship W2581341171A5027811958 @default.
• W2581341171 hasAuthorship W2581341171A5029722841 @default.
• W2581341171 hasAuthorship W2581341171A5031524718 @default.
• W2581341171 hasAuthorship W2581341171A5031900268 @default.
• W2581341171 hasAuthorship W2581341171A5034393745 @default.
• W2581341171 hasAuthorship W2581341171A5034680061 @default.
• W2581341171 hasAuthorship W2581341171A5035398527 @default.
• W2581341171 hasAuthorship W2581341171A5036985315 @default.
• W2581341171 hasAuthorship W2581341171A5041745367 @default.
• W2581341171 hasAuthorship W2581341171A5044869604 @default.
• W2581341171 hasAuthorship W2581341171A5045518627 @default.
• W2581341171 hasAuthorship W2581341171A5045569134 @default.
• W2581341171 hasAuthorship W2581341171A5049017377 @default.
• W2581341171 hasAuthorship W2581341171A5056272944 @default.
• W2581341171 hasAuthorship W2581341171A5065993610 @default.
• W2581341171 hasAuthorship W2581341171A5070003191 @default.
• W2581341171 hasAuthorship W2581341171A5081879832 @default.
• W2581341171 hasAuthorship W2581341171A5082045927 @default.
• W2581341171 hasAuthorship W2581341171A5084298817 @default.
• W2581341171 hasAuthorship W2581341171A5089614080 @default.
• W2581341171 hasAuthorship W2581341171A5091882595 @default.
• W2581341171 hasConcept C126322002 @default.
• W2581341171 hasConcept C126838900 @default.
• W2581341171 hasConcept C141071460 @default.
• W2581341171 hasConcept C167135981 @default.
• W2581341171 hasConcept C2775842073 @default.
• W2581341171 hasConcept C2775934546 @default.
• W2581341171 hasConcept C2777058707 @default.
• W2581341171 hasConcept C2778559949 @default.
• W2581341171 hasConcept C2779338263 @default.
• W2581341171 hasConcept C2989005 @default.
• W2581341171 hasConcept C71924100 @default.
• W2581341171 hasConceptScore W2581341171C126322002 @default.
• W2581341171 hasConceptScore W2581341171C126838900 @default.
• W2581341171 hasConceptScore W2581341171C141071460 @default.
• W2581341171 hasConceptScore W2581341171C167135981 @default.
• W2581341171 hasConceptScore W2581341171C2775842073 @default.
• W2581341171 hasConceptScore W2581341171C2775934546 @default.
• W2581341171 hasConceptScore W2581341171C2777058707 @default.
• W2581341171 hasConceptScore W2581341171C2778559949 @default.
• W2581341171 hasConceptScore W2581341171C2779338263 @default.
• W2581341171 hasConceptScore W2581341171C2989005 @default.
• W2581341171 hasConceptScore W2581341171C71924100 @default.
• W2581341171 hasLocation W25813411711 @default.
• W2581341171 hasOpenAccess W2581341171 @default.
• W2581341171 hasPrimaryLocation W25813411711 @default.
• W2581341171 hasRelatedWork W123535201 @default.
• W2581341171 hasRelatedWork W1577052032 @default.
• W2581341171 hasRelatedWork W1901895983 @default.
• W2581341171 hasRelatedWork W2056910838 @default.
• W2581341171 hasRelatedWork W2231614042 @default.
• W2581341171 hasRelatedWork W2337949273 @default.

• next